دورية أكاديمية
أعرض في EDS

Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study.

التفاصيل البيبلوغرافية
العنوان: Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study.
المؤلفون: Mistler CB; Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA colleen.mistler@uconn.edu.; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA., Shrestha R; Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA.; University of Connecticut Institute for Collaboration on Health Intervention and Policy, Storrs, Connecticut, USA., Gunstad J; Department of Psychology, Kent State University, Kent, Ohio, USA., Collins L; Department of Social and Behavioral Science, New York University College of Global Public Health, New York, New York, USA., Madden L; Department of Internal Medicine-AIDS, Yale University School of Medicine, New Haven, Connecticut, USA.; Apt Foundation Inc, New Haven, Connecticut, USA., Huedo-Medina T; Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA.; Department of Clinical, Health Psychology and Research Methods, University of the Basque Country, Bilbao, Spain., Sibilio B; University of Connecticut Institute for Collaboration on Health Intervention and Policy, Storrs, Connecticut, USA., Copenhaver NM; Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA., Copenhaver M; Department of Allied Health Sciences, University of Connecticut, Storrs, Connecticut, USA.; University of Connecticut Institute for Collaboration on Health Intervention and Policy, Storrs, Connecticut, USA.
المصدر: BMJ open [BMJ Open] 2023 Jun 30; Vol. 13 (6), pp. e071688. Date of Electronic Publication: 2023 Jun 30.
نوع المنشور: Clinical Trial Protocol; Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
مواضيع طبية MeSH: Anti-HIV Agents*/therapeutic use , Cognitive Dysfunction*/prevention & control , Cognitive Dysfunction*/drug therapy , HIV Infections*/prevention & control , HIV Infections*/drug therapy , Opioid-Related Disorders*/prevention & control , Opioid-Related Disorders*/drug therapy , Pre-Exposure Prophylaxis*/methods , Substance Abuse, Intravenous*/epidemiology, Humans
مستخلص: Introduction: People who inject drugs (PWID) have remained a contributor to the consistent HIV incidence rates in the US for decades. Pre-exposure prophylaxis (PrEP) is a promising biomedical intervention for HIV prevention among individuals at risk for HIV infection, including PWID. However, PWID report the lowest rates of PrEP uptake and adherence among at-risk groups. Tailored HIV prevention interventions must include strategies that compensate for cognitive dysfunction among PWID.
Methods and Analysis: Using the multiphase optimisation strategy, we will be conducting a 16-condition factorial experiment to investigate the effects of four different accommodation strategy components to compensate for cognitive dysfunction among 256 PWID on medication for opioid use disorder. This innovative approach will inform optimisation of a highly effective intervention to enhance PWID's ability to process and utilise HIV prevention content to improve PrEP adherence and HIV risk reduction in a drug treatment setting.
Ethics and Dissemination: The institutional review board at the University of Connecticut approved this protocol (H22-0122) with an institutional reliance agreement with APT Foundation Inc. All participants are required to sign an informed consent form prior to engaging in any study protocols. The results of this study will be disseminated on national and international platforms through presentations at major conferences and journals.
Trial Registration Number: NCT05669534.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
References: J Neurovirol. 2011 Feb;17(1):3-16. (PMID: 21174240)
BMC Psychiatry. 2019 Jul 24;19(1):228. (PMID: 31340791)
Am J Geriatr Psychiatry. 2013 Mar;21(3):242-50. (PMID: 23395191)
BMC Public Health. 2017 May 4;17(1):383. (PMID: 28472928)
AIDS Behav. 2013 Nov;17(9):2902-13. (PMID: 23835735)
J Int AIDS Soc. 2015 Dec 14;18:20499. (PMID: 26673880)
Psychopharmacology (Berl). 2012 Jun;221(3):361-87. (PMID: 22441659)
Brain Inj. 2004 May;18(5):461-70. (PMID: 15195794)
Contemp Clin Trials. 2017 Aug;59:1-12. (PMID: 28479216)
Trials. 2019 Dec 16;20(1):728. (PMID: 31842963)
Brain Inj. 2018;32(13-14):1601-1611. (PMID: 30240277)
Subst Abus. 2011 Jan;32(1):16-26. (PMID: 21302180)
AIDS Behav. 2016 Aug;20(8):1646-57. (PMID: 27052845)
Behav Res Ther. 2005 Jul;43(7):831-42. (PMID: 15896281)
J Pharm Biomed Anal. 2016 Apr 15;122:16-20. (PMID: 26829517)
Arch Intern Med. 1998 Sep 14;158(16):1789-95. (PMID: 9738608)
J Addict Dis. 2021 Apr-Jun;39(2):166-174. (PMID: 33047651)
Psychol Bull. 1992 May;111(3):455-74. (PMID: 1594721)
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90. (PMID: 22935078)
J Consult Clin Psychol. 2012 Aug;80(4):700-6. (PMID: 22545736)
Psychol Addict Behav. 2001 Jun;15(2):83-8. (PMID: 11419234)
Exp Clin Psychopharmacol. 2009 Oct;17(5):337-44. (PMID: 19803633)
J Assoc Nurses AIDS Care. 2017 Jul - Aug;28(4):612-621. (PMID: 28478870)
Perspect Psychol Sci. 2014 Mar;9(2):161-79. (PMID: 25544856)
J Pharm Biomed Anal. 2011 Sep 10;56(2):390-401. (PMID: 21715120)
AIDS Behav. 2021 May;25(5):1490-1506. (PMID: 32749627)
HIV Clin Trials. 2004 Mar-Apr;5(2):74-9. (PMID: 15116282)
Psychiatr Clin North Am. 2010 Sep;33(3):497-509. (PMID: 20599129)
Curr Psychiatry Rep. 2010 Feb;12(1):20-7. (PMID: 20425306)
Contemp Clin Trials. 2015 Sep;44:95-102. (PMID: 26253181)
Health Psychol. 2003 Mar;22(2):223-8. (PMID: 12683743)
Subst Abus. 2014;35(4):387-90. (PMID: 25148203)
J Atten Disord. 2006 Nov;10(2):150-9. (PMID: 17085625)
J Consult Clin Psychol. 1999 Aug;67(4):563-70. (PMID: 10450627)
Psychol Bull. 2006 May;132(3):354-80. (PMID: 16719566)
Appl Neuropsychol Adult. 2022 Jul-Aug;29(4):462-468. (PMID: 32463730)
J Psychoactive Drugs. 2003 Apr-Jun;35(2):209-18. (PMID: 12924743)
J Dual Diagn. 2011 Jan 1;7(4):207-227. (PMID: 22383864)
Indian J Psychol Med. 2016 May-Jun;38(3):172-81. (PMID: 27335510)
AIDS Behav. 2018 Aug;22(8):2640-2649. (PMID: 29582199)
Neuropsychol Rehabil. 2019 Jan;29(1):1-21. (PMID: 27873549)
Behav Cogn Psychother. 2009 Mar;37(2):141-50. (PMID: 19364415)
J Affect Disord. 2013 Jul;149(1-3):1-13. (PMID: 23528438)
Int J Environ Res Public Health. 2022 Aug 01;19(15):. (PMID: 35954802)
J Addict Dis. 2023 Apr-Jun;41(2):120-127. (PMID: 35615880)
J Atten Disord. 2008 Nov;12(3):218-26. (PMID: 18192618)
J Acquir Immune Defic Syndr. 2004 Oct 1;37 Suppl 2:S78-87. (PMID: 15385903)
J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019)
Alzheimers Dement (Amst). 2018 Nov 03;10:773-781. (PMID: 30505927)
Patient Prefer Adherence. 2020 Jan 16;14:107-118. (PMID: 32021122)
Soc Sci Med. 1991;32(6):705-14. (PMID: 2035047)
Psychol Addict Behav. 2006 Sep;20(3):241-53. (PMID: 16938062)
Psychol Methods. 2009 Sep;14(3):202-24. (PMID: 19719358)
Am J Drug Alcohol Abuse. 2007;33(1):109-20. (PMID: 17366251)
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697. (PMID: 27572401)
J Atten Disord. 2008 May;11(6):728-36. (PMID: 17712167)
J Geriatr Psychiatry Neurol. 2020 May;33(3):155-160. (PMID: 31500493)
Psychol Rep. 1990 Dec;67(3 Pt 2):1091-100. (PMID: 2084735)
Gen Psychiatr. 2021 Aug 16;34(4):e100412. (PMID: 34504995)
Front Public Health. 2022 Feb 10;10:825988. (PMID: 35223742)
Lancet Infect Dis. 2014 Sep;14(9):820-9. (PMID: 25065857)
J Int Neuropsychol Soc. 2012 Jan;18(1):1-19. (PMID: 22152338)
AIDS Care. 2017 Sep;29(9):1144-1148. (PMID: 28478706)
Transl Behav Med. 2014 Sep;4(3):238-51. (PMID: 25264464)
J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19434. (PMID: 25724507)
J Subst Abuse Treat. 2000 Jul;19(1):15-22. (PMID: 10867296)
Arch Gen Psychiatry. 1992 Nov;49(11):881-7. (PMID: 1444726)
Schizophr Bull. 2005 Oct;31(4):922-30. (PMID: 16037481)
J Head Trauma Rehabil. 2007 Sep-Oct;22(5):303-13. (PMID: 17878772)
Subst Abuse. 2015 Mar 12;9:17-24. (PMID: 25861219)
J Subst Abuse Treat. 2004 Mar;26(2):67-78. (PMID: 15050083)
AIDS Patient Care STDS. 2009 Apr;23(4):277-87. (PMID: 19260773)
Front Immunol. 2019 Oct 18;10:2445. (PMID: 31681322)
Arch Gen Psychiatry. 1994 Dec;51(12):989-97. (PMID: 7979888)
BMJ. 2006 Feb 25;332(7539):455-9. (PMID: 16452102)
Arch Phys Med Rehabil. 2019 Aug;100(8):1515-1533. (PMID: 30926291)
Am J Alzheimers Dis Other Demen. 2018 May;33(3):184-191. (PMID: 29357670)
Contemp Clin Trials. 2013 Jan;34(1):45-52. (PMID: 23010608)
J Consult Clin Psychol. 1997 Jun;65(3):510-4. (PMID: 9170775)
Am J Psychiatry. 1999 Nov;156(11):1758-64. (PMID: 10553740)
Ann N Y Acad Sci. 2014 Oct;1327:94-111. (PMID: 25204847)
Psychopharmacology (Berl). 2007 Mar;190(4):517-30. (PMID: 17136401)
معلومات مُعتمدة: K24 DA051344 United States DA NIDA NIH HHS; R01 DA055534 United States DA NIDA NIH HHS; K01 DA051346 United States DA NIDA NIH HHS; T32 DA019426 United States DA NIDA NIH HHS
فهرسة مساهمة: Keywords: Infectious disease/HIV; STATISTICS & RESEARCH METHODS; Substance misuse
سلسلة جزيئية: ClinicalTrials.gov NCT05669534
المشرفين على المادة: 0 (Anti-HIV Agents)
تواريخ الأحداث: Date Created: 20230703 Date Completed: 20230717 Latest Revision: 20240508
رمز التحديث: 20240508
مُعرف محوري في PubMed: PMC10314648
DOI: 10.1136/bmjopen-2023-071688
PMID: 37399447
قاعدة البيانات: MEDLINE
الوصف
تدمد:2044-6055
DOI:10.1136/bmjopen-2023-071688